View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
THURSDAY, Nov. 15 (HealthDay News) -- In patients with Angelman syndrome, a genetic neurodevelopmental disorder with motor impairments similar to Parkinson's disease, treatment with levodopa (L-DOPA) may help but may also have unexpected consequences, according to an experimental study published online Nov. 12 in the Journal of Clinical Investigation.
To investigate why treatment with L-DOPA improves the parkinsonian features of Angelman syndrome, Thorfinn T. Riday, from the University of North Carolina at Chapel Hill, and colleagues studied mice lacking the maternal copy of the ubiquitin ligase E3A (UBE3A) gene, which is known to cause Angelman syndrome.
The researchers found that the mice had behavioral deficits, but these were due to abnormal dopamine signaling rather than loss of dopaminergic neurons or impaired dopamine synthesis. In addition, in the UBE3Am−/p+ mice, dopamine release was increased in the mesolimbic (reward) pathway but decreased in the nigrostriatal (motor) pathway. The authors note that treating Parkinson's disease patients with L-DOPA also improves motor symptoms but has adverse effects on reward-mediated behaviors.
"These observations, together with our findings that dopaminergic dysfunction in Angelman syndrome may be pathway specific, raise a cautionary note for ongoing clinical trials of L-DOPA in individuals with Angelman syndrome," Riday and colleagues conclude.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top